Pancreatic Cancer

Pancreatic cancer, or pancreatic ductal adenocarcinoma (PDAC), has a five-year survival rate of less than 10% due to advanced-stage diagnosis. For the small proportion (10–20%) of patients with early diagnosis prior to metastasis, resection of the pancreatic tumor offers the best chance for survival (five-year survival rate of 20%). However, recurrence is still common (71%) despite curative intent, and disease-free survival is rare, indicating that surgery alone may be inadequate treatment for PDAC. The high incidence of metastatic diagnoses and poor outcome of many PDAC patients emphasizes the need for effective biomarkers to guide early diagnosis, real-time disease monitoring, and clinical decision-making in order to maximize patient survival.

Morphometric analysis of individual cells detected by HDSCA3.0 in all PDAC samples.

• Shishido SN, Lin E, Nissen N, Courcoubetis G, Suresh D, Mason J, Osipov A, Hendifar A, Lewis M, Gaddam S, Pandol S, Kuhn P, Lo S. Cancer-related cells and oncosomes in the liquid biopsy of pancreatic cancer patients undergoing surgery. npj Precis. Onc. 8, 36 (2024). https: doi.org/10.1038/s41698-024-00521-0. 

• Shishido SN, Suresh D, Courcoubetis G, Ye B, Lin E, Mason J, Park K, Lewis M, Wang R, Lo S, Kuhn P. Determining the efficacy of ExThera Seraph100 blood filtration in patients diagnosed with pancreatic cancer through the liquid biopsy. BJC Rep 2, 47 (2024).